Inactief instrument

Andere talen Antibe Therapeutics Inc Toronto S.E.

Aandelen

ATE

CA0370251039

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Antibe Therapeutics Inc. Announces Board Resignations	24/04
Antibe Therapeutics Inc. Announces Board Resignations	09/04
Antibe Therapeutics Inc. Announces FDA Clinical Hold on Otenaproxesul	01/04
Antibe Therapeutics Inc. Announces Formation of Executive Committee	01/04
Antibe Reported Q3 2024 Interim Financial and Operating Results	14/02
Antibe Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	14/02
Antibe Extending Early Warrant Exercise Incentive Program	01/02
Antibe Therapeutics Announced Early Warrant Exercise Incentive Program	29/12
Antibe Therapeutics Up 4% After Announcing Amendment To Warrant Extension, Price Changes	12/12
Antibe Therapeutics Reports Q3 2023 Net and Comprehensive Loss of $5 Million	13/11
Antibe Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	13/11
Antibe Therapeutics Inc. Reports PK Results of First Clinical Study of Otenaproxesul?s New Formulation	09/11
Antibe Completes First Clinical Study of Otenaproxesul?s New Formulation	01/11
Antibe Initiates First Clinical Study of Otenaproxesul?s New Formulation	18-10-23
Antibe Therapeutics Receives Approval to Initiate PK/PD Study of Otenaproxesul	28-09-23
Antibe Therapeutics Inc. Receives Approval to Initiate PK/PD Study of Otenaproxesul	28-09-23
Antibe Therapeutics Reports Q1 Loss of $5.8 Million	14-08-23
Antibe Therapeutics Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	14-08-23
Antibe Therapeutics Reports 2023 Year-End Results	29-06-23
Antibe Therapeutics Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	29-06-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Antibe Therapeutics Inc Toronto S.E.

Aandelen

ATE

CA0370251039

Andere talen

Filters